Department of Pharmacy, University of Naples Federico II, via D. Montesano 49, Naples, 80131, Italy.
Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Viikinkaari 9, Helsinki, FI-00014, Finland.
Small. 2022 Oct;18(41):e2204732. doi: 10.1002/smll.202204732. Epub 2022 Sep 11.
Redox-responsive silica drug delivery systems are synthesized by aeco-friendly diatomite source to achieve on-demand release of peptide nucleic acid (PNA) in tumor reducing microenvironment, aiming to inhibit the immune checkpoint programmed cell death 1 receptor/programmed cell death receptor ligand 1 (PD-1/PD-L1) in cancer cells. The nanoparticles (NPs) are coated with polyethylene glycol chains as gatekeepers to improve their physicochemical properties and control drug release through the cleavable disulfide bonds (S-S) in a reductive environment. This study describes different chemical conditions to achieve the highest NPs' surface functionalization yield, exploring both multistep and one-pot chemical functionalization strategies. The best formulation is used for covalent PNA conjugation via the S-S bond reaching a loading degree of 306 ± 25 µg mg . These systems are used for in vitro studies to evaluate the kinetic release, biocompatibility, cellular uptake, and activity on different cancer cells expressing high levels of PD-L1. The obtained results prove the safety of the NPs up to 200 µg mL and their advantage for controlling and enhancing the PNA intracellular release as well as antitumor activity. Moreover, the downregulation of PD-L1 observed only with MDA-MB-231 cancer cells paves the way for targeted immunotherapy.
基于环保型硅藻土来源合成了氧化还原响应型二氧化硅药物递送系统,以实现在肿瘤还原微环境中按需释放肽核酸(PNA),从而抑制癌细胞中的免疫检查点程序性细胞死亡 1 受体/程序性细胞死亡配体 1(PD-1/PD-L1)。纳米颗粒(NPs)涂有聚乙二醇链作为门控物,以改善其物理化学性质,并通过还原环境中可裂解的二硫键(S-S)控制药物释放。本研究描述了不同的化学条件以实现最高的 NPs 表面功能化产率,探索了多步和一步化学功能化策略。使用最佳配方通过 S-S 键进行共价 PNA 缀合,达到 306 ± 25 µg mg 的载药量。这些系统用于体外研究,以评估动力学释放、生物相容性、细胞摄取以及对表达高水平 PD-L1 的不同癌细胞的活性。所得结果证明了 NPs 的安全性高达 200 µg mL,并且它们有利于控制和增强 PNA 的细胞内释放以及抗肿瘤活性。此外,仅在 MDA-MB-231 癌细胞中观察到 PD-L1 的下调为靶向免疫疗法铺平了道路。